Mirum Pharmaceuticals, Inc. announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
